API tools faq
paste
Advertisement
LACabeza

Bivalirudin

LACabeza
Jan 4th, 2016
334
0
Never
Add comment
Not a member of Pastebin yet? Sign Up, it unlocks many cool features!
XML 43.20 KB | None | 0 0
raw download clone embed print report
  1. <drug type="biotech" created="2005-06-13" updated="2013-09-13">
  2.   <drugbank-id primary="true">DB00006</drugbank-id>
  3.   <drugbank-id>BIOD00076</drugbank-id>
  4.   <drugbank-id>BTD00076</drugbank-id>
  5.   <name>Bivalirudin</name>
  6.   <description>Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure. </description>
  7.   <cas-number>128270-60-0</cas-number>
  8.   <groups>
  9.     <group>approved</group>
  10.     <group>investigational</group>
  11.   </groups>
  12.   <general-references># Seybert AL, Coons JC, Zerumsky K: Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin? Pharmacotherapy. 2006 Feb;26(2):229-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16466327&#13;
  13. # Dager WE, Dougherty JA, Nguyen PH, Militello MA, Smythe MA: Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy. 2007 Apr;27(4):564-87. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17381384&#13;
  14. # Dang CH, Durkalski VL, Nappi JM: Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy. 2006 Apr;26(4):461-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16553503&#13;
  15. # Robson R: The use of bivalirudin in patients with renal impairment. J Invasive Cardiol. 2000 Dec;12 Suppl F:33F-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11156732&#13;
  16. # Van De Car DA, Rao SV, Ohman EM: Bivalirudin: a review of the pharmacology and clinical application. Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1673-81. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21108549&#13;
  17. # Shammas NW: Bivalirudin: pharmacology and clinical applications. Cardiovasc Drug Rev. 2005 Winter;23(4):345-60. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16614733&#13;
  18. # Gleason TG, Chengelis CP, Jackson CB, Lindstrom P: A 24-hour continuous infusion study of bivalirudin in the rat. Int J Toxicol. 2003 May-Jun;22(3):195-206. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12851152</general-references>
  19.   <synthesis-reference>Avi Tovi, Chaim Eidelman, Shimon Shushan, Alon Hagi, Alexander Ivchenko, Gabriel-Marcus Butilca, Leah Bar-Oz, Tehila Gadi, Gil Zaovi, "Process for production of Bivalirudin." U.S. Patent US20070093423, issued April 26, 2007.</synthesis-reference>
  20.   <indication>For treatment of heparin-induced thrombocytopenia and for the&#13;
  21. prevention of thrombosis. Bivalirudin is indicated for use in&#13;
  22. patients undergoing percutaneous coronary intervention (PCI), in&#13;
  23. patients at moderate to high risk acute coronary syndromes due to&#13;
  24. unstable angina or non-ST segment elevation in whom a PCI is planned.</indication>
  25.   <pharmacodynamics>Bivalirudin directly and reversibly inhibits thrombin by specifically binding both to the catalytic site and to the anion-binding exosite of circulating and clot-bound thrombin.  The action of bivalirudin is reversible because thrombin will slowly cleave the thrombin-bivalirudin bond which recovers the active site of thrombin. </pharmacodynamics>
  26.   <mechanism-of-action>Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.</mechanism-of-action>
  27.   <toxicity>Based on a study by Gleason et al., the no-observed-adverse-effect level (NOAEL) for bivalirudin, administered to rats via intravenous infusion over a 24-hour period, was 2000 mg/kg/24 h.</toxicity>
  28.   <metabolism>80% proteolytic cleavage</metabolism>
  29.   <absorption>Following intravenous administration, bivalirudin exhibits linear&#13;
  30. pharmacokinetics .  The mean steady state concentration is 12.3 +/-&#13;
  31. 1.7mcg/mL after administration of an intravenous bolus of 1mg/kg&#13;
  32. followd by a 2.5mg/kg/hr intravenous infusion given over 4 hours.</absorption>
  33.   <half-life>* Normal renal function: 25 min (in normal conditions)&#13;
  34. * Creatinine clearance 10-29mL/min: 57min&#13;
  35. * Dialysis-dependant patients: 3.5h</half-life>
  36.   <protein-binding>Other than thrombin and red blood cells, bivalirudin does not bind to&#13;
  37. plasma proteins.</protein-binding>
  38.   <route-of-elimination>Bivalirudin is cleared from plasma by a combination of renal mechanisms (20%) and proteolytic cleavage.</route-of-elimination>
  39.   <volume-of-distribution>0.2L/kg</volume-of-distribution>
  40.   <clearance>* 3.4 mL/min/kg [Normal renal function]&#13;
  41. * 3.4 mL/min/kg [mild renal function]&#13;
  42. * 2.7 mL/min/kg [moderate renal function]&#13;
  43. * 2.8 mL/min/kg [severe renal function]&#13;
  44. * 1 mL/min/kg [Dialysis-dependent patients]</clearance>
  45.   <classification>
  46.     <description/>
  47.     <direct-parent>Peptides</direct-parent>
  48.     <kingdom>Organic Compounds</kingdom>
  49.     <superclass>Organic Acids</superclass>
  50.     <class>Carboxylic Acids and Derivatives</class>
  51.     <subclass>Amino Acids, Peptides, and Analogues</subclass>
  52.   </classification>
  53.   <salts/>
  54.   <synonyms/>
  55.   <products>
  56.     <product>
  57.       <name>Angiomax</name>
  58.       <ndc-id>55154-2275_799d3b00-809b-4abc-989c-05faccec49f8</ndc-id>
  59.       <ndc-product-code>55154-2275</ndc-product-code>
  60.       <dpd-id/>
  61.       <started-marketing-on>2000-12-15</started-marketing-on>
  62.       <ended-marketing-on/>
  63.       <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
  64.       <strength>250 mg</strength>
  65.       <route>intravenous</route>
  66.       <fda-application-number>NDA020873</fda-application-number>
  67.       <generic>false</generic>
  68.       <over-the-counter>false</over-the-counter>
  69.       <approved>true</approved>
  70.       <country>US</country>
  71.       <source>FDA NDC</source>
  72.     </product>
  73.     <product>
  74.       <name>Angiomax</name>
  75.       <ndc-id/>
  76.       <ndc-product-code/>
  77.       <dpd-id>02246533</dpd-id>
  78.       <started-marketing-on>2003-05-08</started-marketing-on>
  79.       <ended-marketing-on/>
  80.       <dosage-form>powder for solution</dosage-form>
  81.       <strength>250 mg</strength>
  82.       <route>intravenous</route>
  83.       <fda-application-number/>
  84.       <generic>false</generic>
  85.       <over-the-counter>false</over-the-counter>
  86.       <approved>true</approved>
  87.       <country>Canada</country>
  88.       <source>DPD</source>
  89.     </product>
  90.     <product>
  91.       <name>Angiomax</name>
  92.       <ndc-id>65293-001_3ff32af9-cb93-41e5-99ef-a7c162b35d92</ndc-id>
  93.       <ndc-product-code>65293-001</ndc-product-code>
  94.       <dpd-id/>
  95.       <started-marketing-on>2000-12-15</started-marketing-on>
  96.       <ended-marketing-on/>
  97.       <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
  98.       <strength>250 mg</strength>
  99.       <route>intravenous</route>
  100.       <fda-application-number>NDA020873</fda-application-number>
  101.       <generic>false</generic>
  102.       <over-the-counter>false</over-the-counter>
  103.       <approved>true</approved>
  104.       <country>US</country>
  105.       <source>FDA NDC</source>
  106.     </product>
  107.     <product>
  108.       <name>Bivalirudin</name>
  109.       <ndc-id>0409-8300_4530ae1c-394e-44f4-89c0-bacb0e6991a0</ndc-id>
  110.       <ndc-product-code>0409-8300</ndc-product-code>
  111.       <dpd-id/>
  112.       <started-marketing-on>2015-07-14</started-marketing-on>
  113.       <ended-marketing-on/>
  114.       <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
  115.       <strength>250 mg</strength>
  116.       <route>intravenous</route>
  117.       <fda-application-number>ANDA090811</fda-application-number>
  118.       <generic>true</generic>
  119.       <over-the-counter>false</over-the-counter>
  120.       <approved>true</approved>
  121.       <country>US</country>
  122.       <source>FDA NDC</source>
  123.     </product>
  124.     <product>
  125.       <name>Bivalirudin</name>
  126.       <ndc-id>0409-8300_fa3b34fe-d666-42e6-a1d4-3dbcfab7a384</ndc-id>
  127.       <ndc-product-code>0409-8300</ndc-product-code>
  128.       <dpd-id/>
  129.       <started-marketing-on>2015-07-14</started-marketing-on>
  130.       <ended-marketing-on/>
  131.       <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
  132.       <strength>250 mg</strength>
  133.       <route>intravenous</route>
  134.       <fda-application-number>ANDA090816</fda-application-number>
  135.       <generic>true</generic>
  136.       <over-the-counter>false</over-the-counter>
  137.       <approved>true</approved>
  138.       <country>US</country>
  139.       <source>FDA NDC</source>
  140.     </product>
  141.     <product>
  142.       <name>Bivalirudin</name>
  143.       <ndc-id>0781-3158_def5f702-a45c-4a38-a49b-a017bb7f5f3c</ndc-id>
  144.       <ndc-product-code>0781-3158</ndc-product-code>
  145.       <dpd-id/>
  146.       <started-marketing-on>2015-06-15</started-marketing-on>
  147.       <ended-marketing-on/>
  148.       <dosage-form>injection, powder, lyophilized, for solution</dosage-form>
  149.       <strength>250 mg</strength>
  150.       <route>intravenous</route>
  151.       <fda-application-number>NDA020873</fda-application-number>
  152.       <generic>false</generic>
  153.       <over-the-counter>false</over-the-counter>
  154.       <approved>true</approved>
  155.       <country>US</country>
  156.       <source>FDA NDC</source>
  157.     </product>
  158.   </products>
  159.   <international-brands>
  160.     <international-brand>
  161.       <name>Angiox</name>
  162.       <company/>
  163.     </international-brand>
  164.   </international-brands>
  165.   <mixtures>
  166.     <mixture>
  167.       <name>Bivalirudin</name>
  168.       <ingredients>Bivalirudin</ingredients>
  169.     </mixture>
  170.     <mixture>
  171.       <name>Bivalirudin</name>
  172.       <ingredients>Bivalirudin</ingredients>
  173.     </mixture>
  174.     <mixture>
  175.       <name>Bivalirudin</name>
  176.       <ingredients>Bivalirudin</ingredients>
  177.     </mixture>
  178.     <mixture>
  179.       <name>Angiomax</name>
  180.       <ingredients>Bivalirudin</ingredients>
  181.     </mixture>
  182.     <mixture>
  183.       <name>Angiomax</name>
  184.       <ingredients>Bivalirudin</ingredients>
  185.     </mixture>
  186.     <mixture>
  187.       <name>Angiomax</name>
  188.       <ingredients>Bivalirudin</ingredients>
  189.     </mixture>
  190.   </mixtures>
  191.   <packagers>
  192.     <packager>
  193.       <name>Ben Venue Laboratories Inc.</name>
  194.       <url>http://www.benvenue.com</url>
  195.     </packager>
  196.     <packager>
  197.       <name>Oryx Pharmaceuticals Inc.</name>
  198.       <url/>
  199.     </packager>
  200.     <packager>
  201.       <name>Sepracor Pharmaceuticals Inc.</name>
  202.       <url>http://www.sepracor.com</url>
  203.     </packager>
  204.     <packager>
  205.       <name>The Medicines Co.</name>
  206.       <url>http://www.themedicinescompany.com</url>
  207.     </packager>
  208.   </packagers>
  209.   <manufacturers>
  210.     <manufacturer generic="false">The medicines co</manufacturer>
  211.   </manufacturers>
  212.   <prices>
  213.     <price>
  214.       <description>Angiomax 250 mg vial</description>
  215.       <cost currency="USD">780.0</cost>
  216.       <unit>vial</unit>
  217.     </price>
  218.   </prices>
  219.   <categories>
  220.     <category>
  221.       <category>Antithrombins</category>
  222.       <mesh-id/>
  223.     </category>
  224.   </categories>
  225.   <affected-organisms>
  226.     <affected-organism>Humans and other mammals</affected-organism>
  227.   </affected-organisms>
  228.   <dosages>
  229.     <dosage>
  230.       <form>Powder for solution</form>
  231.       <route>intravenous</route>
  232.       <strength>250 mg</strength>
  233.     </dosage>
  234.     <dosage>
  235.       <form>Injection, powder, lyophilized, for solution</form>
  236.       <route>intravenous</route>
  237.       <strength>250 mg</strength>
  238.     </dosage>
  239.   </dosages>
  240.   <atc-codes>
  241.     <atc-code code="B01AE06">
  242.       <level code="B">BLOOD AND BLOOD FORMING ORGANS</level>
  243.       <level code="B01">ANTITHROMBOTIC AGENTS</level>
  244.       <level code="B01A">ANTITHROMBOTIC AGENTS</level>
  245.       <level code="B01AE">Direct thrombin inhibitors</level>
  246.     </atc-code>
  247.   </atc-codes>
  248.   <ahfs-codes>
  249.     <ahfs-code>20:12.04.12</ahfs-code>
  250.   </ahfs-codes>
  251.   <patents>
  252.     <patent>
  253.       <number>2065150</number>
  254.       <country>Canada</country>
  255.       <approved>1999-12-14</approved>
  256.       <expires>2010-08-17</expires>
  257.     </patent>
  258.     <patent>
  259.       <number>5196404</number>
  260.       <country>United States</country>
  261.       <approved>1993-05-23</approved>
  262.       <expires>2010-05-23</expires>
  263.     </patent>
  264.     <patent>
  265.       <number>7582727</number>
  266.       <country>United States</country>
  267.       <approved>2009-01-27</approved>
  268.       <expires>2029-01-27</expires>
  269.     </patent>
  270.   </patents>
  271.   <food-interactions>
  272.     <food-interaction>Dan shen, dong quai, evening primrose oil, gingko, policosanol, willow bark</food-interaction>
  273.     <food-interaction>Echinacea</food-interaction>
  274.   </food-interactions>
  275.   <drug-interactions>
  276.     <drug-interaction>
  277.       <drugbank-id>DB00054</drugbank-id>
  278.       <name>Abciximab</name>
  279.       <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
  280.     </drug-interaction>
  281.     <drug-interaction>
  282.       <drugbank-id>DB01418</drugbank-id>
  283.       <name>Acenocoumarol</name>
  284.       <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
  285.     </drug-interaction>
  286.     <drug-interaction>
  287.       <drugbank-id>DB00945</drugbank-id>
  288.       <name>Acetylsalicylic acid</name>
  289.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  290.     </drug-interaction>
  291.     <drug-interaction>
  292.       <drugbank-id>DB00009</drugbank-id>
  293.       <name>Alteplase</name>
  294.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  295.     </drug-interaction>
  296.     <drug-interaction>
  297.       <drugbank-id>DB00029</drugbank-id>
  298.       <name>Anistreplase</name>
  299.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  300.     </drug-interaction>
  301.     <drug-interaction>
  302.       <drugbank-id>DB06605</drugbank-id>
  303.       <name>Apixaban</name>
  304.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  305.     </drug-interaction>
  306.     <drug-interaction>
  307.       <drugbank-id>DB04272</drugbank-id>
  308.       <name>Citric Acid</name>
  309.       <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
  310.     </drug-interaction>
  311.     <drug-interaction>
  312.       <drugbank-id>DB06695</drugbank-id>
  313.       <name>Dabigatran etexilate</name>
  314.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  315.     </drug-interaction>
  316.     <drug-interaction>
  317.       <drugbank-id>DB06779</drugbank-id>
  318.       <name>Dalteparin</name>
  319.       <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
  320.     </drug-interaction>
  321.     <drug-interaction>
  322.       <drugbank-id>DB01254</drugbank-id>
  323.       <name>Dasatinib</name>
  324.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  325.     </drug-interaction>
  326.     <drug-interaction>
  327.       <drugbank-id>DB01609</drugbank-id>
  328.       <name>Deferasirox</name>
  329.       <description>Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.</description>
  330.     </drug-interaction>
  331.     <drug-interaction>
  332.       <drugbank-id>DB03619</drugbank-id>
  333.       <name>Deoxycholic Acid</name>
  334.       <description>Anticoagulants may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased.</description>
  335.     </drug-interaction>
  336.     <drug-interaction>
  337.       <drugbank-id>DB00304</drugbank-id>
  338.       <name>Desogestrel</name>
  339.       <description>May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.</description>
  340.     </drug-interaction>
  341.     <drug-interaction>
  342.       <drugbank-id>DB00266</drugbank-id>
  343.       <name>Dicoumarol</name>
  344.       <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
  345.     </drug-interaction>
  346.     <drug-interaction>
  347.       <drugbank-id>DB00378</drugbank-id>
  348.       <name>Dydrogesterone</name>
  349.       <description>May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.</description>
  350.     </drug-interaction>
  351.     <drug-interaction>
  352.       <drugbank-id>DB00974</drugbank-id>
  353.       <name>Edetic Acid</name>
  354.       <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
  355.     </drug-interaction>
  356.     <drug-interaction>
  357.       <drugbank-id>DB09075</drugbank-id>
  358.       <name>Edoxaban</name>
  359.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  360.     </drug-interaction>
  361.     <drug-interaction>
  362.       <drugbank-id>DB01225</drugbank-id>
  363.       <name>Enoxaparin</name>
  364.       <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
  365.     </drug-interaction>
  366.     <drug-interaction>
  367.       <drugbank-id>DB08794</drugbank-id>
  368.       <name>Ethyl biscoumacetate</name>
  369.       <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
  370.     </drug-interaction>
  371.     <drug-interaction>
  372.       <drugbank-id>DB00569</drugbank-id>
  373.       <name>Fondaparinux sodium</name>
  374.       <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
  375.     </drug-interaction>
  376.     <drug-interaction>
  377.       <drugbank-id>DB06730</drugbank-id>
  378.       <name>Gestodene</name>
  379.       <description>May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.</description>
  380.     </drug-interaction>
  381.     <drug-interaction>
  382.       <drugbank-id>DB01109</drugbank-id>
  383.       <name>Heparin</name>
  384.       <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
  385.     </drug-interaction>
  386.     <drug-interaction>
  387.       <drugbank-id>DB00078</drugbank-id>
  388.       <name>Ibritumomab</name>
  389.       <description>Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.</description>
  390.     </drug-interaction>
  391.     <drug-interaction>
  392.       <drugbank-id>DB09053</drugbank-id>
  393.       <name>Ibrutinib</name>
  394.       <description>May enhance the adverse/toxic effect of Anticoagulants.</description>
  395.     </drug-interaction>
  396.     <drug-interaction>
  397.       <drugbank-id>DB09079</drugbank-id>
  398.       <name>Nintedanib</name>
  399.       <description>Anticoagulants may enhance the adverse/toxic effect of Nintedanib. Specifically, the risk for bleeding may be increased.</description>
  400.     </drug-interaction>
  401.     <drug-interaction>
  402.       <drugbank-id>DB08935</drugbank-id>
  403.       <name>Obinutuzumab</name>
  404.       <description>Anticoagulants may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased.</description>
  405.     </drug-interaction>
  406.     <drug-interaction>
  407.       <drugbank-id>DB00686</drugbank-id>
  408.       <name>Pentosan Polysulfate</name>
  409.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  410.     </drug-interaction>
  411.     <drug-interaction>
  412.       <drugbank-id>DB00498</drugbank-id>
  413.       <name>Phenindione</name>
  414.       <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
  415.     </drug-interaction>
  416.     <drug-interaction>
  417.       <drugbank-id>DB00946</drugbank-id>
  418.       <name>Phenprocoumon</name>
  419.       <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
  420.     </drug-interaction>
  421.     <drug-interaction>
  422.       <drugbank-id>DB00396</drugbank-id>
  423.       <name>Progesterone</name>
  424.       <description>May diminish the therapeutic effect of Anticoagulants. More specifically, the potential prothrombotic effects of some progestins and progestin-estrogen combinations may counteract anticoagulant effects.</description>
  425.     </drug-interaction>
  426.     <drug-interaction>
  427.       <drugbank-id>DB00015</drugbank-id>
  428.       <name>Reteplase</name>
  429.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  430.     </drug-interaction>
  431.     <drug-interaction>
  432.       <drugbank-id>DB01207</drugbank-id>
  433.       <name>Ridogrel</name>
  434.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  435.     </drug-interaction>
  436.     <drug-interaction>
  437.       <drugbank-id>DB06228</drugbank-id>
  438.       <name>Rivaroxaban</name>
  439.       <description>Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.</description>
  440.     </drug-interaction>
  441.     <drug-interaction>
  442.       <drugbank-id>DB01398</drugbank-id>
  443.       <name>Salicylate-sodium</name>
  444.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  445.     </drug-interaction>
  446.     <drug-interaction>
  447.       <drugbank-id>DB00086</drugbank-id>
  448.       <name>Streptokinase</name>
  449.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  450.     </drug-interaction>
  451.     <drug-interaction>
  452.       <drugbank-id>DB06206</drugbank-id>
  453.       <name>Sugammadex</name>
  454.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  455.     </drug-interaction>
  456.     <drug-interaction>
  457.       <drugbank-id>DB06271</drugbank-id>
  458.       <name>Sulodexide</name>
  459.       <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
  460.     </drug-interaction>
  461.     <drug-interaction>
  462.       <drugbank-id>DB00031</drugbank-id>
  463.       <name>Tenecteplase</name>
  464.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  465.     </drug-interaction>
  466.     <drug-interaction>
  467.       <drugbank-id>DB09070</drugbank-id>
  468.       <name>Tibolone</name>
  469.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  470.     </drug-interaction>
  471.     <drug-interaction>
  472.       <drugbank-id>DB00932</drugbank-id>
  473.       <name>Tipranavir</name>
  474.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  475.     </drug-interaction>
  476.     <drug-interaction>
  477.       <drugbank-id>DB00374</drugbank-id>
  478.       <name>Treprostinil</name>
  479.       <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
  480.     </drug-interaction>
  481.     <drug-interaction>
  482.       <drugbank-id>DB00013</drugbank-id>
  483.       <name>Urokinase</name>
  484.       <description>May enhance the anticoagulant effect of Anticoagulants.</description>
  485.     </drug-interaction>
  486.     <drug-interaction>
  487.       <drugbank-id>DB00163</drugbank-id>
  488.       <name>Vitamin E</name>
  489.       <description>May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.</description>
  490.     </drug-interaction>
  491.     <drug-interaction>
  492.       <drugbank-id>DB09030</drugbank-id>
  493.       <name>Vorapaxar</name>
  494.       <description>May enhance the adverse/toxic effect of Anticoagulants. More specifically, this combination is expected to increase the risk of bleeding.</description>
  495.     </drug-interaction>
  496.     <drug-interaction>
  497.       <drugbank-id>DB00682</drugbank-id>
  498.       <name>Warfarin</name>
  499.       <description>May enhance the anticoagulant effect of other Anticoagulants.</description>
  500.     </drug-interaction>
  501.   </drug-interactions>
  502.   <sequences>
  503.     <sequence format="FASTA">&gt;Bivalirudin sequence
  504. FPRPGGGGNGDFEEIPEEYL</sequence>
  505.   </sequences>
  506.   <experimental-properties>
  507.     <property>
  508.       <kind>Hydrophobicity</kind>
  509.       <value>-0.985</value>
  510.       <source/>
  511.     </property>
  512.     <property>
  513.       <kind>Isoelectric Point</kind>
  514.       <value>3.91</value>
  515.       <source/>
  516.     </property>
  517.     <property>
  518.       <kind>Molecular Weight</kind>
  519.       <value>2180.2853</value>
  520.       <source/>
  521.     </property>
  522.     <property>
  523.       <kind>Molecular Formula</kind>
  524.       <value>C98H138N24O33</value>
  525.       <source/>
  526.     </property>
  527.   </experimental-properties>
  528.   <external-identifiers>
  529.     <external-identifier>
  530.       <resource>Drugs Product Database (DPD)</resource>
  531.       <identifier>12945</identifier>
  532.     </external-identifier>
  533.     <external-identifier>
  534.       <resource>KEGG Drug</resource>
  535.       <identifier>D03136</identifier>
  536.     </external-identifier>
  537.     <external-identifier>
  538.       <resource>National Drug Code Directory</resource>
  539.       <identifier>65293-001-01</identifier>
  540.     </external-identifier>
  541.     <external-identifier>
  542.       <resource>PharmGKB</resource>
  543.       <identifier>PA10032</identifier>
  544.     </external-identifier>
  545.     <external-identifier>
  546.       <resource>Wikipedia</resource>
  547.       <identifier>Bivalirudin</identifier>
  548.     </external-identifier>
  549.   </external-identifiers>
  550.   <external-links>
  551.     <external-link>
  552.       <resource>RxList</resource>
  553.       <url>http://www.rxlist.com/cgi/generic/angiomax.htm</url>
  554.     </external-link>
  555.     <external-link>
  556.       <resource>Drugs.com</resource>
  557.       <url>http://www.drugs.com/cdi/bivalirudin.html</url>
  558.     </external-link>
  559.   </external-links>
  560.   <pathways>
  561.     <pathway>
  562.       <smpdb-id>SMP00277</smpdb-id>
  563.       <name>Bivalirudin Action Pathway</name>
  564.       <drugs>
  565.         <drug>
  566.           <drugbank-id>DB00006</drugbank-id>
  567.           <name>Bivalirudin</name>
  568.         </drug>
  569.         <drug>
  570.           <drugbank-id>DB01022</drugbank-id>
  571.           <name>Phylloquinone</name>
  572.         </drug>
  573.         <drug>
  574.           <drugbank-id>DB01373</drugbank-id>
  575.           <name>Calcium</name>
  576.         </drug>
  577.       </drugs>
  578.       <enzymes>
  579.         <uniprot-id>P00734</uniprot-id>
  580.         <uniprot-id>P00748</uniprot-id>
  581.         <uniprot-id>P02452</uniprot-id>
  582.         <uniprot-id>P03952</uniprot-id>
  583.         <uniprot-id>P03951</uniprot-id>
  584.         <uniprot-id>P00740</uniprot-id>
  585.         <uniprot-id>P00451</uniprot-id>
  586.         <uniprot-id>P12259</uniprot-id>
  587.         <uniprot-id>P00742</uniprot-id>
  588.         <uniprot-id>P02671</uniprot-id>
  589.         <uniprot-id>P02675</uniprot-id>
  590.         <uniprot-id>P02679</uniprot-id>
  591.         <uniprot-id>P00488</uniprot-id>
  592.         <uniprot-id>P05160</uniprot-id>
  593.         <uniprot-id>P00747</uniprot-id>
  594.         <uniprot-id>P00750</uniprot-id>
  595.         <uniprot-id>P08709</uniprot-id>
  596.         <uniprot-id>P13726</uniprot-id>
  597.         <uniprot-id>Q9BQB6</uniprot-id>
  598.         <uniprot-id>P38435</uniprot-id>
  599.       </enzymes>
  600.     </pathway>
  601.   </pathways>
  602.   <reactions/>
  603.   <snp-effects/>
  604.   <snp-adverse-drug-reactions/>
  605.   <targets>
  606.     <target>
  607.       <id>BE0000048</id>
  608.       <name>Prothrombin</name>
  609.       <organism>Human</organism>
  610.       <actions>
  611.         <action>inhibitor</action>
  612.       </actions>
  613.       <references># Scatena R: Bivalirudin: a new generation antithrombotic drug. Expert Opin Investig Drugs. 2000 May;9(5):1119-27. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11060732&#13;
  614. # Bates ER: Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes. Curr Cardiol Rep. 2001 Sep;3(5):348-54. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11504570&#13;
  615. # Gladwell TD: Bivalirudin: a direct thrombin inhibitor. Clin Ther. 2002 Jan;24(1):38-58. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11833835&#13;
  616. # Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao T: Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 2002 Apr;143(4):585-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11923794&#13;
  617. # Carswell CI, Plosker GL: Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs. 2002;62(5):841-70. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11929334&#13;
  618. # Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11752352</references>
  619.       <known-action>yes</known-action>
  620.       <polypeptide id="P00734" source="Swiss-Prot">
  621.     <name>Prothrombin</name>
  622.     <general-function>Involved in blood clotting cascade</general-function>
  623.     <specific-function>Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C</specific-function>
  624.     <gene-name>F2</gene-name>
  625.     <locus>11p11-q12</locus>
  626.     <cellular-location>Secreted protein; extracellular space</cellular-location>
  627.     <transmembrane-regions>None</transmembrane-regions>
  628.     <signal-regions/>
  629.     <theoretical-pi>5.7</theoretical-pi>
  630.     <molecular-weight>70037.0</molecular-weight>
  631.     <chromosome-location/>
  632.     <organism ncbi-taxonomy-id="9606">Human</organism>
  633.     <external-identifiers>
  634.       <external-identifier>
  635.         <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
  636.         <identifier>HGNC:3535</identifier>
  637.       </external-identifier>
  638.       <external-identifier>
  639.         <resource>GenAtlas</resource>
  640.         <identifier>F2</identifier>
  641.       </external-identifier>
  642.       <external-identifier>
  643.         <resource>GeneCards</resource>
  644.         <identifier>F2</identifier>
  645.       </external-identifier>
  646.       <external-identifier>
  647.         <resource>GenBank Gene Database</resource>
  648.         <identifier>M17262</identifier>
  649.       </external-identifier>
  650.       <external-identifier>
  651.         <resource>GenBank Protein Database</resource>
  652.         <identifier>339641</identifier>
  653.       </external-identifier>
  654.       <external-identifier>
  655.         <resource>UniProtKB</resource>
  656.         <identifier>P00734</identifier>
  657.       </external-identifier>
  658.       <external-identifier>
  659.         <resource>UniProt Accession</resource>
  660.         <identifier>THRB_HUMAN</identifier>
  661.       </external-identifier>
  662.     </external-identifiers>
  663.     <synonyms>
  664.       <synonym>Activated Factor II [IIa]</synonym>
  665.       <synonym>Coagulation factor II</synonym>
  666.       <synonym>EC 3.4.21.5</synonym>
  667.       <synonym>Prothrombin precursor</synonym>
  668.       <synonym>Thrombin</synonym>
  669.     </synonyms>
  670.     <amino-acid-sequence format="FASTA">&gt;Prothrombin precursor
  671. MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC
  672. VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV
  673. NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE
  674. CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA
  675. QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG
  676. DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI
  677. DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN
  678. DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP
  679. VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST
  680. RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY
  681. GFYTHVFRLKKWIQKVIDQFGE</amino-acid-sequence>
  682.     <gene-sequence format="FASTA">&gt;1869 bp
  683. ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC
  684. CTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG
  685. GTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTAGAGCGAGAGTGC
  686. GTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG
  687. GATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT
  688. GCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG
  689. AACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT
  690. GAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC
  691. GACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA
  692. TGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA
  693. GGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG
  694. TACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA
  695. CAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC
  696. TTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT
  697. GGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA
  698. GATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC
  699. CAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT
  700. CTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC
  701. GACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG
  702. CTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG
  703. GTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT
  704. GACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACAAGGTACGAGCGAAACATTGAAAAG
  705. ATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC
  706. CGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT
  707. GTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG
  708. GTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC
  709. AGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC
  710. CGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA
  711. GGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC
  712. CGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT
  713. GGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT
  714. GGAGAGTAG</gene-sequence>
  715.     <pfams>
  716.       <pfam>
  717.         <identifier>PF00594</identifier>
  718.         <name>Gla</name>
  719.       </pfam>
  720.       <pfam>
  721.         <identifier>PF00051</identifier>
  722.         <name>Kringle</name>
  723.       </pfam>
  724.       <pfam>
  725.         <identifier>PF00089</identifier>
  726.         <name>Trypsin</name>
  727.       </pfam>
  728.     </pfams>
  729.     <go-classifiers>
  730.       <go-classifier>
  731.         <category>component</category>
  732.         <description>extracellular region</description>
  733.       </go-classifier>
  734.       <go-classifier>
  735.         <category>function</category>
  736.         <description>catalytic activity</description>
  737.       </go-classifier>
  738.       <go-classifier>
  739.         <category>function</category>
  740.         <description>thrombin activity</description>
  741.       </go-classifier>
  742.       <go-classifier>
  743.         <category>function</category>
  744.         <description>hydrolase activity</description>
  745.       </go-classifier>
  746.       <go-classifier>
  747.         <category>function</category>
  748.         <description>calcium ion binding</description>
  749.       </go-classifier>
  750.       <go-classifier>
  751.         <category>function</category>
  752.         <description>peptidase activity</description>
  753.       </go-classifier>
  754.       <go-classifier>
  755.         <category>function</category>
  756.         <description>ion binding</description>
  757.       </go-classifier>
  758.       <go-classifier>
  759.         <category>function</category>
  760.         <description>endopeptidase activity</description>
  761.       </go-classifier>
  762.       <go-classifier>
  763.         <category>function</category>
  764.         <description>cation binding</description>
  765.       </go-classifier>
  766.       <go-classifier>
  767.         <category>function</category>
  768.         <description>serine-type endopeptidase activity</description>
  769.       </go-classifier>
  770.       <go-classifier>
  771.         <category>function</category>
  772.         <description>binding</description>
  773.       </go-classifier>
  774.       <go-classifier>
  775.         <category>process</category>
  776.         <description>hemostasis</description>
  777.       </go-classifier>
  778.       <go-classifier>
  779.         <category>process</category>
  780.         <description>blood coagulation</description>
  781.       </go-classifier>
  782.       <go-classifier>
  783.         <category>process</category>
  784.         <description>metabolism</description>
  785.       </go-classifier>
  786.       <go-classifier>
  787.         <category>process</category>
  788.         <description>macromolecule metabolism</description>
  789.       </go-classifier>
  790.       <go-classifier>
  791.         <category>process</category>
  792.         <description>protein metabolism</description>
  793.       </go-classifier>
  794.       <go-classifier>
  795.         <category>process</category>
  796.         <description>proteolysis</description>
  797.       </go-classifier>
  798.       <go-classifier>
  799.         <category>process</category>
  800.         <description>cellular protein metabolism</description>
  801.       </go-classifier>
  802.       <go-classifier>
  803.         <category>process</category>
  804.         <description>organismal physiological process</description>
  805.       </go-classifier>
  806.       <go-classifier>
  807.         <category>process</category>
  808.         <description>regulation of body fluids</description>
  809.       </go-classifier>
  810.       <go-classifier>
  811.         <category>process</category>
  812.         <description>physiological process</description>
  813.       </go-classifier>
  814.     </go-classifiers>
  815.   </polypeptide>
  816.     </target>
  817.   </targets>
  818.   <enzymes>
  819.     <enzyme position="1">
  820.       <id>BE0001075</id>
  821.       <name>Myeloperoxidase</name>
  822.       <organism>Human</organism>
  823.       <actions>
  824.         <action>inhibitor</action>
  825.       </actions>
  826.       <references># Rudolph V, Rudolph TK, Schopfer FJ, Bonacci G, Lau D, Szocs K, Klinke A, Meinertz T, Freeman BA, Baldus S: Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008 Nov;327(2):324-31. Epub 2008 Aug 13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18701766[</references>
  827.       <known-action>unknown</known-action>
  828.       <polypeptide id="P05164" source="Swiss-Prot">
  829.     <name>Myeloperoxidase</name>
  830.     <general-function>Involved in peroxidase activity</general-function>
  831.     <specific-function>Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity</specific-function>
  832.     <gene-name>MPO</gene-name>
  833.     <locus>17q23.1</locus>
  834.     <cellular-location>Lysosome</cellular-location>
  835.     <transmembrane-regions>None</transmembrane-regions>
  836.     <signal-regions/>
  837.     <theoretical-pi>9.14</theoretical-pi>
  838.     <molecular-weight>83870.0</molecular-weight>
  839.     <chromosome-location/>
  840.     <organism ncbi-taxonomy-id="9606">Human</organism>
  841.     <external-identifiers>
  842.       <external-identifier>
  843.         <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
  844.         <identifier>HGNC:7218</identifier>
  845.       </external-identifier>
  846.       <external-identifier>
  847.         <resource>GenAtlas</resource>
  848.         <identifier>MPO</identifier>
  849.       </external-identifier>
  850.       <external-identifier>
  851.         <resource>GeneCards</resource>
  852.         <identifier>MPO</identifier>
  853.       </external-identifier>
  854.       <external-identifier>
  855.         <resource>GenBank Gene Database</resource>
  856.         <identifier>J02694</identifier>
  857.       </external-identifier>
  858.       <external-identifier>
  859.         <resource>GenBank Protein Database</resource>
  860.         <identifier>189040</identifier>
  861.       </external-identifier>
  862.       <external-identifier>
  863.         <resource>UniProtKB</resource>
  864.         <identifier>P05164</identifier>
  865.       </external-identifier>
  866.       <external-identifier>
  867.         <resource>UniProt Accession</resource>
  868.         <identifier>PERM_HUMAN</identifier>
  869.       </external-identifier>
  870.     </external-identifiers>
  871.     <synonyms>
  872.       <synonym>EC 1.11.1.7</synonym>
  873.       <synonym>MPO</synonym>
  874.       <synonym>Myeloperoxidase precursor</synonym>
  875.     </synonyms>
  876.     <amino-acid-sequence format="FASTA">&gt;Myeloperoxidase precursor
  877. MGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS
  878. LVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH
  879. VALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC
  880. NNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD
  881. QLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND
  882. PRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL
  883. GLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL
  884. REHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR
  885. SYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE
  886. GGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN
  887. AWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL
  888. LACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS
  889. NSYPRDFVNCSTLPALNLASWREAS</amino-acid-sequence>
  890.     <gene-sequence format="FASTA">&gt;2238 bp
  891. ATGGGGGTTCCCTTCTTCTCTTCTCTCAGATGCATGGTGGACTTAGGACCTTGCTGGGCT
  892. GGGGGTCTCACTGCAGAGATGAAGCTGCTTCTGGCCCTAGCAGGGCTCCTGGCCATTCTG
  893. GCCACGCCCCAGCCCTCTGAAGGTGCTGCTCCAGCTGTCCTGGGGGAGGTGGACACCTCG
  894. TTGGTGCTGAGCTCCATGGAGGAGGCCAAGCAGCTGGTGGACAAGGCCTACAAGGAGCGG
  895. CGGGAAAGCATCAAGCAGCGGCTTCGCAGCGGCTCAGCCAGCCCCATGGAACTCCTATCC
  896. TACTTCAAGCAGCCGGTGGCAGCCACCAGGACGGCGGTGAGGGCCGCTGACTACCTGCAC
  897. GTGGCTCTAGACCTGCTGGAGAGGAAGCTGCGGTCCCTGTGGCGAAGGCCATTCAATGTC
  898. ACTGATGTGCTGACGCCCGCCCAGCTGAATGTGTTGTCCAAGTCAAGCGGCTGCGCCTAC
  899. CAGGACGTGGGGGTGACTTGCCCGGAGCAGGACAAATACCGCACCATCACCGGGATGTGC
  900. AACAACAGACGCAGCCCCACGCTGGGGGCCTCCAACCGTGCCTTTGTGCGCTGGCTGCCG
  901. GCGGAGTATGAGGACGGCTTCTCTCTTCCCTACGGCTGGACGCCCGGGGTCAAGCGCAAC
  902. GGCTTCCCGGTGGCTCTGGCTCGCGCGGTCTCCAACGAGATCGTGCGCTTCCCCACTGAT
  903. CAGCTGACTCCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCCAGCTGTTGGAC
  904. CACGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTCACTGGCGTCAAC
  905. TGCGAGACCAGCTGCGTTCAGCAGCCGCCCTGCTTCCCGCTCAAGATCCCGCCCAATGAC
  906. CCCCGCATCAAGAACCAAGCCGACTGCATCCCGTTCTTCCGCTCCTGCCCGGCTTGCCCC
  907. GGGAGCAACATCACCATCCGCAACCAGATCAACGCGCTCACTTCCTTCGTGGACGCCAGC
  908. ATGGTGTACGGCAGCGAGGAGCCCCTGGCCAGGAACCTGCGCAACATGTCCAACCAGCTG
  909. GGGCTGCTGGCCGTCAACCAGCGCTTCCAAGACAACGGCCGGGCCCTGCTGCCCTTTGAC
  910. AACCTGCACGATGACCCCTGTCTCCTCACCAACCGCTCAGCGCGCATCCCCTGCTTCCTG
  911. GCAGGGGACACCCGTTCCAGTGAGATGCCCGAGCTCACCTCCATGCACACCCTCTTACTT
  912. CGGGAGCACAACCGGCTGGCCACAGAGCTCAAGAGCCTGAACCCTAGGTGGGATGGGGAG
  913. AGGCTCTACCAGGAAGCCCGGAAGATCGTGGGGGCCATGGTCCAGATCATCACTTACCGG
  914. GACTACCTGCCCCTGGTGCTGGGGCCAACGGCCATGAGGAAGTACCTGCCCACGTACCGT
  915. TCCTACAATGACTCAGTGGACCCACGCATCGCCAACGTCTTCACCAATGCCTTCCGCTAC
  916. GGCCACACCCTCATCCAACCCTTCATGTTCCGCCTGGACAATCGGTACCAGCCCATGGAA
  917. CCCAACCCCCGTGTCCCCCTCAGCAGGGTCTTTTTTGCCTCCTGGAGGGTCGTGCTGGAA
  918. GGTGGCATTGACCCCATCCTCCGGGGCCTCATGGCCACCCCTGCCAAGCTGAATCGTCAG
  919. AACCAAATTGCAGTGGATGAGATCCGGGAGCGATTGTTTGAGCAGGTCATGAGGATTGGG
  920. CTGGACCTGCCTGCTCTGAACATGCAGCGCAGCAGGGACCACGGCCTCCCAGGATACAAT
  921. GCCTGGAGGCGCTTCTGTGGGCTCCCGCAGCCTGAAACTGTGGGCCAGCTGGGCACGGTG
  922. CTGAGGAACCTGAAATTGGCGAGGAAACTGATGGAGCAGTATGGCACGCCCAACAACATC
  923. GACATCTGGATGGGCGGCGTGTCCGAGCCTCTGAAGCGCAAAGGCCGCGTGGGCCCACTC
  924. CTCGCCTGCATCATCGGTACCCAGTTCAGGAAGCTCCGGGATGGTGATCGGTTTTGGTGG
  925. GAGAACGAGGGTGTGTTCAGCATGCAGCAGCGACAGGCCCTGGCCCAGATCTCATTGCCC
  926. CGGATCATCTGCGACAACACAGGCATCACCACCGTGTCTAAGAACAACATCTTCATGTCC
  927. AACTCATATCCCCGGGACTTTGTCAACTGCAGTACACTTCCTGCATTGAACCTGGCTTCC
  928. TGGAGGGAAGCCTCCTAG</gene-sequence>
  929.     <pfams>
  930.       <pfam>
  931.         <identifier>PF03098</identifier>
  932.         <name>An_peroxidase</name>
  933.       </pfam>
  934.     </pfams>
  935.     <go-classifiers>
  936.       <go-classifier>
  937.         <category>function</category>
  938.         <description>antioxidant activity</description>
  939.       </go-classifier>
  940.       <go-classifier>
  941.         <category>function</category>
  942.         <description>peroxidase activity</description>
  943.       </go-classifier>
  944.       <go-classifier>
  945.         <category>process</category>
  946.         <description>cellular metabolism</description>
  947.       </go-classifier>
  948.       <go-classifier>
  949.         <category>process</category>
  950.         <description>oxygen and reactive oxygen species metabolism</description>
  951.       </go-classifier>
  952.       <go-classifier>
  953.         <category>process</category>
  954.         <description>response to oxidative stress</description>
  955.       </go-classifier>
  956.       <go-classifier>
  957.         <category>process</category>
  958.         <description>physiological process</description>
  959.       </go-classifier>
  960.       <go-classifier>
  961.         <category>process</category>
  962.         <description>metabolism</description>
  963.       </go-classifier>
  964.     </go-classifiers>
  965.   </polypeptide>
  966.       <inhibition-strength>unknown</inhibition-strength>
  967.       <induction-strength>unknown</induction-strength>
  968.     </enzyme>
  969.   </enzymes>
  970.   <carriers/>
  971.   <transporters/>
  972. </drug>
Advertisement
Add Comment
Please, Sign In to add comment
Advertisement
Public Pastes
Advertisement
We use cookies for various purposes including analytics. By continuing to use Pastebin, you agree to our use of cookies as described in the Cookies Policy.  OK, I Understand
Not a member of Pastebin yet?
Sign Up, it unlocks many cool features!